Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to close at record levels Friday, with the Dow Jones hitting 33,800 and the S&P 500 topping 4,100, as investors ignored co...
Could These Biotech Stocks Be The Best Stocks To Invest In Right Now? You can’t deny that biotech stocks have and continue to receive a whole lot of attention from investors now. Accordingly, this is because of the current pandemic where biotech companies are continuously...
Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...
Gainers: Celcuity (CELC) +56%, GeoVax Labs (GOVX) +36%, Affimed (AFMD) +24%, Tenax Therapeutics (TENX) +22%, Genetic Technologies (GENE) +13%.Losers: Novo Integrated Sciences (NVOS) -24%, Provention Bio (PRVB) -21%, Virpax ...
Celcuity (CELC) shares are up 48% in morning trading after the company and Pfizer (PFE) announced a major licensing deal after the closing bell yesterday.The agreement, worth up to $340M, calls for for Celcuity to receive exclusive global rights to Pfizer’s gedatolisib, ...
Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The end of the week is almost here but that doesn’t mean investors can relax just yet. Instead, you need to keep up with the top pre-market movers and make sure to finish out this week of trading strong! Source: S...
Celcuity (CELC) has entered into a global licensing agreement with Pfizer (PFE) for exclusive rights to Pfizer’s gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor. Gedatolisib is in clinical development for the treatment of patients with ER+/HER2-negative advanced or metastatic...
Preliminary Phase 1b Data - 53 of the 88 evaluable patients (60%) had an objective response - - Gedatolisib showed a potentially differentiated safety and tolerability profile - Corporate Update - Entered $25 million debt financing agreement with Innova...
-Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted - Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy - ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...